Barcelona-developed MAF Test reaches US to improve breast cancer treatment

The test, created by Inbiomotion (IRB Barcelona spin-off), helps identify patients who may benefit from adjuvant therapies.

El test MAF, desenvolupat a Barcelona, arriba als EUA per millorar el tractament del càncer de mama

Institut de Recerca Biomèdica

The MAF Test®, a diagnostic tool developed by the IRB Barcelona spin-off Inbiomotion, is now available in the United States through an agreement with NeoGenomics Laboratories. This test helps identify early-stage breast cancer patients who could benefit from adjuvant therapies, while avoiding unnecessary treatments for others.

The MAF Test®, a result of research from Dr. Roger Gomis' lab at IRB Barcelona, assists oncologists in predicting recurrence and survival rates in early-stage breast cancer patients. It is estimated to potentially benefit around 258,000 patients diagnosed annually in the country.
The test identifies MAF-negative tumors (80% of cases), in which adjuvant bisphosphonate therapy has shown to improve disease-free survival and reduce the risk of death. Conversely, patients with MAF-positive tumors do not show benefits from these treatments, thus avoiding potentially harmful overtreatment.
The clinical utility of the test is supported by studies such as the AZURE and NSABP-B34 trials, published in journals like The Lancet Oncology and the Journal of the National Cancer Institute. Furthermore, it has been included in the SEOM-GEICAM-SOLTI clinical guidelines for 2025.
The availability in the United States marks a significant milestone in Inbiomotion's international expansion, with the test already offered in Spain, Portugal, Italy, the United Kingdom, Ireland, South Korea, and Sub-Saharan Africa.
“

"We are very pleased that oncologists and their patients in the United States now have access to the MAF Test® through NeoGenomics, a frontrunner in innovative oncology testing. U.S. availability marks a major step in making precision medicine a reality for early-stage breast cancer patients worldwide. By helping physicians identify which patients are more likely to benefit from specific therapies, we aim to improve outcomes and reduce unnecessary treatments."

Joël Jean-Mairet · Executive Chairperson of Inbiomotion
“

"We believe that expanding access to the MAF Test® in the United States will have a tangible impact on patient care. It supports the movement toward more precise, biology-driven treatment strategies in breast cancer, benefiting both patients and healthcare systems. The results of AZURE and NSABP-B34 studies show that the MAF Test® could identify 8 out of 10 of the 258,000 early-stage breast cancer patients diagnosed each year who may have improved outcomes."

Ralf van den Berg · Chief Operating Officer of Inbiomotion
Inbiomotion is a spin-off of IRB Barcelona and ICREA, founded in 2011. The company has developed the MAF Test®, a diagnostic kit based on detecting MAF gene amplification, to promote precision medicine and improve breast cancer treatment.
Based on information from the official source: IRB Barcelona - Institut de Recerca Biomèdica (20/11/2026)